162 related articles for article (PubMed ID: 15299073)
21. Identification and activities of human carboxylesterases for the activation of CPT-11, a clinically approved anticancer drug.
Senter PD; Beam KS; Mixan B; Wahl AF
Bioconjug Chem; 2001; 12(6):1074-80. PubMed ID: 11716702
[TBL] [Abstract][Full Text] [Related]
22. Overexpression of a rabbit liver carboxylesterase sensitizes human tumor cells to CPT-11.
Danks MK; Morton CL; Pawlik CA; Potter PM
Cancer Res; 1998 Jan; 58(1):20-2. PubMed ID: 9426050
[TBL] [Abstract][Full Text] [Related]
23. Proficient metabolism of irinotecan by a human intestinal carboxylesterase.
Khanna R; Morton CL; Danks MK; Potter PM
Cancer Res; 2000 Sep; 60(17):4725-8. PubMed ID: 10987276
[TBL] [Abstract][Full Text] [Related]
24. Characterization of CPT-11 converting carboxylesterase activity in colon tumor and normal tissues: comparison with p-nitro-phenylacetate converting carboxylesterase activity.
Hennebelle I; Terret C; Chatelut E; Bugat R; Canal P; Guichard S
Anticancer Drugs; 2000 Jul; 11(6):465-70. PubMed ID: 11001387
[TBL] [Abstract][Full Text] [Related]
25. Structural insights into CPT-11 activation by mammalian carboxylesterases.
Bencharit S; Morton CL; Howard-Williams EL; Danks MK; Potter PM; Redinbo MR
Nat Struct Biol; 2002 May; 9(5):337-42. PubMed ID: 11967565
[TBL] [Abstract][Full Text] [Related]
26. Molecular modeling of CPT-11 metabolism by carboxylesterases (CEs): use of pnb CE as a model.
Wierdl M; Morton CL; Nguyen NK; Redinbo MR; Potter PM
Biochemistry; 2004 Feb; 43(7):1874-82. PubMed ID: 14967028
[TBL] [Abstract][Full Text] [Related]
27. Biochemical and molecular analysis of carboxylesterase-mediated hydrolysis of cocaine and heroin.
Hatfield MJ; Tsurkan L; Hyatt JL; Yu X; Edwards CC; Hicks LD; Wadkins RM; Potter PM
Br J Pharmacol; 2010 Aug; 160(8):1916-28. PubMed ID: 20649590
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of human carboxylesterases hCE1 and hiCE by cholinesterase inhibitors.
Tsurkan LG; Hatfield MJ; Edwards CC; Hyatt JL; Potter PM
Chem Biol Interact; 2013 Mar; 203(1):226-30. PubMed ID: 23123248
[TBL] [Abstract][Full Text] [Related]
29. Isolation and partial characterization of a cDNA encoding a rabbit liver carboxylesterase that activates the prodrug irinotecan (CPT-11).
Potter PM; Pawlik CA; Morton CL; Naeve CW; Danks MK
Cancer Res; 1998 Jun; 58(12):2646-51. PubMed ID: 9635592
[TBL] [Abstract][Full Text] [Related]
30. Secreted and tumour targeted human carboxylesterase for activation of irinotecan.
Oosterhoff D; Pinedo HM; van der Meulen IH; de Graaf M; Sone T; Kruyt FA; van Beusechem VW; Haisma HJ; Gerritsen WR
Br J Cancer; 2002 Sep; 87(6):659-64. PubMed ID: 12237777
[TBL] [Abstract][Full Text] [Related]
31. Carboxylesterase-mediated sensitization of human tumor cells to CPT-11 cannot override ABCG2-mediated drug resistance.
Wierdl M; Wall A; Morton CL; Sampath J; Danks MK; Schuetz JD; Potter PM
Mol Pharmacol; 2003 Aug; 64(2):279-88. PubMed ID: 12869632
[TBL] [Abstract][Full Text] [Related]
32. A virus-directed enzyme prodrug therapy approach to purging neuroblastoma cells from hematopoietic cells using adenovirus encoding rabbit carboxylesterase and CPT-11.
Meck MM; Wierdl M; Wagner LM; Burger RA; Guichard SM; Krull EJ; Harris LC; Potter PM; Danks MK
Cancer Res; 2001 Jul; 61(13):5083-9. PubMed ID: 11431345
[TBL] [Abstract][Full Text] [Related]
33. Use of the ornithine decarboxylase promoter to achieve N-MYC-mediated overexpression of a rabbit carboxylesterase to sensitize neuroblastoma cells to CPT-11.
Pawlik CA; Iyengar RV; Krull EJ; Mason SE; Khanna R; Harris LC; Potter PM; Danks MK; Guichard SM
Mol Ther; 2000 May; 1(5 Pt 1):457-63. PubMed ID: 10933967
[TBL] [Abstract][Full Text] [Related]
34. Mouse liver and kidney carboxylesterase (M-LK) rapidly hydrolyzes antitumor prodrug irinotecan and the N-terminal three quarter sequence determines substrate selectivity.
Xie M; Yang D; Wu M; Xue B; Yan B
Drug Metab Dispos; 2003 Jan; 31(1):21-7. PubMed ID: 12485949
[TBL] [Abstract][Full Text] [Related]
35. Selective Inhibitors of Human Liver Carboxylesterase Based on a β-Lapachone Scaffold: Novel Reagents for Reaction Profiling.
Hatfield MJ; Chen J; Fratt EM; Chi L; Bollinger JC; Binder RJ; Bowling J; Hyatt JL; Scarborough J; Jeffries C; Potter PM
J Med Chem; 2017 Feb; 60(4):1568-1579. PubMed ID: 28112927
[TBL] [Abstract][Full Text] [Related]
36. Carboxylesterases 1 and 2 hydrolyze phospho-nonsteroidal anti-inflammatory drugs: relevance to their pharmacological activity.
Wong CC; Cheng KW; Xie G; Zhou D; Zhu CH; Constantinides PP; Rigas B
J Pharmacol Exp Ther; 2012 Feb; 340(2):422-32. PubMed ID: 22085648
[TBL] [Abstract][Full Text] [Related]
37. Hypoxia-targeted over-expression of carboxylesterase as a means of increasing tumour sensitivity to irinotecan (CPT-11).
Matzow T; Cowen RL; Williams KJ; Telfer BA; Flint PJ; Southgate TD; Saunders MP
J Gene Med; 2007 Apr; 9(4):244-52. PubMed ID: 17397102
[TBL] [Abstract][Full Text] [Related]
38. Human carboxylesterase 2 is commonly expressed in tumor tissue and is correlated with activation of irinotecan.
Xu G; Zhang W; Ma MK; McLeod HL
Clin Cancer Res; 2002 Aug; 8(8):2605-11. PubMed ID: 12171891
[TBL] [Abstract][Full Text] [Related]
39. Identification of human intestinal carboxylesterase as the primary enzyme for activation of a doxazolidine carbamate prodrug.
Barthel BL; Torres RC; Hyatt JL; Edwards CC; Hatfield MJ; Potter PM; Koch TH
J Med Chem; 2008 Jan; 51(2):298-304. PubMed ID: 18173233
[TBL] [Abstract][Full Text] [Related]
40. Carboxylesterase Inhibitors: An Update.
Zou LW; Jin Q; Wang DD; Qian QK; Hao DC; Ge GB; Yang L
Curr Med Chem; 2018; 25(14):1627-1649. PubMed ID: 29210644
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
